EX-10.58



 EXHIBIT 10.58 

CONFIDENTIAL TREATMENT REQUESTED 

AMENDMENT NO. 1 TO SUBLICENSE AGREEMENT 

This Amendment is made as of the 30th day of November 1998, between TITAN PHARMACEUTICALS, INC., a corporation organized under the laws of the
State of Delaware and having its principal offices at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 U.S.A. (hereinafter “TITAN”), and NOVARTIS PHARMA A.G., a corporation organized under the laws of Switzerland and having
its principal offices at Lichtstrasse 35, CH 4002, Basel, Switzerland (hereinafter “NOVARTIS”). 
 WITNESSETH 

WHEREAS, the parties have entered into that certain Sublicense Agreement, effective as of November 20. 1997 (the “Principal
Agreement”), whereby, among other things, TITAN granted to NOVARTIS an exclusive sublicense relating to a compound known as Iloperidone; and 

WHEREAS, by this Amendment the parties desire to amend the Principal Agreement. 

NOW THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the pasties hereto agree as follows: 
 1. The
term “Agreement”, as used and defined in the Principal Agreement, shall mean the Principal Agreement as amended by this Amendment. Terms defined in the Principal Agreement and not otherwise defined herein are used herein as defined in the
Principal Agreement. 
 2. Except as otherwise provided herein, the terms and provisions of the Principal Agreement shall be unchanged and
shall continue in full force and effect. 
 3. Appendix A to the Principal Agreement is hereby amended in its entirety to be and read in the
form attached as Appendix A to this Amendment. 
 4. This Amendment may be executed in any number of counterparts, each of which should be
deemed to be an original, but all of which together shall constitute one and the same Amendment. 








 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties hereby intending to be legally bound have caused this
Amendment to be executed and delivered by their proper and duly authorized officers as of the day and year first above written. 
  

									
	NOVARTIS PHARMA A.G.				TITAN PHARMACEUTICALS, INC.
					
	By:		 /s/ Olivier Bassi    /s/ James S. New
				By:		 /s/ Louis R. Bucalo

					
	Date: 		August 27, 1999				Date: 		November 30, 1998









 CONFIDENTIAL TREATMENT REQUESTED 

 

 APPENDIX A 

PATENTS AND PATENT APPLICATIONS (PER SECTION 1.17) 

(As amended per Amendment No. 1 to Sublicense Agreement) 
  


															
	 Country
	  	 Patent Appl. No.
	  	 Filing Date
	  	 Type
	  	 Status
	  	 Patent No.
	  	 Issue Date
	  	 Expiration

Date

		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	

 **** 

  

	****	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS. 










 CONFIDENTIAL TREATMENT REQUESTED 

 


															
	 Country
	 	 Patent Appl. No.
	 	 Filing Date
	 	 Type
	 	 Status
	 	 Patent No.
	 	 Issue Date
	 	 Expiration

Date

		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	

 **** 

  

	****	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS. 










 CONFIDENTIAL TREATMENT REQUESTED 

 


															
	 Country
	 	 Patent Appl. No.
	 	 Filing Date
	 	 Type
	 	 Status
	 	 Patent No.
	 	 Issue Date
	 	 Expiration

Date

		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	

 **** 

  

	****	CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.